Posted on

PharmAla Biotech Registers Trademark for MDMA

PharmAla Biotech Registers Trademark for MDMA

The Company’s clinical-grade GMP MDMA product is now known as “Laneo”

VANCOUVER, June 24, 2022 (Canada Newswire) – PharmAla Biotech (CSE:MDMA) has registered a trademark for its clinical-grade MDMA product, which shall be marketed as Laneo MDMA. PharmAla is currently the only publicly-traded company to have developed a full manufacturing value chain for MDMA.

“While MDMA is a generic drug, there’s a huge difference between illicit drug manufacture and our clinical-grade product. Only one is appropriate for use in scientific research: Laneo MDMA,“ said Nick Kadysh, CEO of PharmAla Biotech. “With this trademark registration, PharmAla continues to establish itself as the leader in MDMA manufacture, research, and development.”

A number of customers have already made deposits for Laneo MDMA, and the company anticipates initial product deliveries to be made in Fall of 2022. Laneo MDMA is initially available to customers in both a 40mg formulated clinical trial capsule and as pure Active Pharmaceutical Ingredient (API) which can be compounded by a qualified pharmacist. In the future, a range of drug product formulations can be developed.

“We’re speaking to customers every day who are excited to initiate clinical trials with MDMA – but they are unable to do so because up until now, they didn’t have access to clinical trial supply of drug product,” said David Purcell, Director of Sales at PharmAla Biotech. “PharmAla Biotech’s Laneo MDMA is the answer.”

For more information, please visit www.PharmAla.ca, where you can sign up to receive regular new updates.

ABOUT PHARMALA

PharmAla Biotech Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, and to develop novel drugs in the same class. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. Our team of dedicated professionals includes regulatory experts, scientists, and biomanufacturing professionals. PharmAla has built what it believes to be North America’s first cGMP MDMA value chain, encompassing GMP manufacturing of Active Pharmaceutical Ingredient (API), and drug product formulation. PharmAla’s research and development unit has also begun preclinical research into two patented Novel Chemical Entities (NCEs) based on MDXX class molecules, with proof-of-concept research currently ongoing at the University of Arkansas Medical School.

Posted on

AIkido Inc. Announces the Formation of a New Financial Services Subsidiary

AIkido Inc. Announces the Formation of a New Financial Services Subsidiary

Long-Range Strategy Seeks Diversification into Three Key Industries

NEW YORK, June 24, 2022 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) announced the formation of a wholly owned subsidiary with the purpose of making strategic investments and acquisitions across the fintech and financial services industries. The new subsidiary is expected to be the centerpiece of a long-range plan to diversify AIkido’s business beyond biotechnology, in order to reduce volatility and mitigate risk while increasing revenue and enhancing shareholder value.

The new subsidiary will leverage the extensive capital markets expertise of AIkido’s board of directors to identify investment opportunities and acquisition targets in wealth management, investment banking, alternative investments, and asset management with the goal of transforming and optimizing operations with a synergistic and accretive business model. The Company is in the process of recruiting additional top-tier talent to implement the strategy.

Anthony Hayes, CEO of AIkido stated, “Our board is made up of some of the most accomplished Wall St. executives, so we are fully confident that the financial services sector is the right next step for AIkido and our overall plan is the right path forward for our company. Our vision is to merge world-class talent with best-in-class technology to acquire revenue generating assets to drive shareholder value,” Hayes added.

“Beyond acquisitions in the financial services industries, AIkido intends to create two additional subsidiaries in the industries of health and wellness and innovative technology. Our investment portfolio was set up along these same lines. For example, the legacy biotech assets and our investment in ASP Isotopes, Kerna Health, will be part of our health and wellness subsidiary. Whereas our investments in Epics Games, SpaceX, and Discord, are foundational to our innovation subsidiary. Our assets are part of a long-term strategy to own operational and revenue generating companies in the key high-growth sectors that we have identified for investment. The proceeds from the investments in each industry, some of which we expect to receive this year, will allow us to further fund and grow revenue generating businesses in those sectors. And just like financial services, the recruitment of top talent within each subsidiary is necessary for execution. We are committed as a Company to keep shareholders informed and will provide additional information when we are able. We thank shareholders for their patience and believe we have the proper plan to navigate through the notable downturn in the biotechnology sector and build a diversified company of revenue generating assets.”

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics. The Company’s platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Cautionary Note on Forward-Looking Statements

This press release and any statements of stockholders, directors, employees, representatives and partners of AIkido Pharma, Inc. (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results (including, without limitation, the impact of the Reverse Stock Split described in this release) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

Contact:

Investor Relations:

Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

SOURCE AIkido Pharma Inc.

Posted on

Braxia Scientific CEO to Deliver Keynote Address at H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond

Braxia Scientific CEO to Deliver Keynote Address at H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond

TORONTO, ONTARIO June 24, 2022 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the H.C. Wainwright Global Investment Conference from June 27 – 28, 2022 in New York.

Braxia Scientific CEO Dr. Roger McIntyre will deliver two live presentations at the conference beginning with a Keynote address – Introduction to the State of Mental Healthcare – to kick off the conference on Monday, June 27 at 8:15 a.m. ET

Dr. McIntyre, will also deliver a second presentation on Monday, June 27 at 4:00 p.m. ET providing an overview of the Braxia’s business, including its progress on increasing access to novel ketamine and psychedelic treatments for patients with depression, while also expanding the clinical research infrastructure required to execute on the Company’s growing pipeline of registered clinical trials alongside third-party sponsors.

Braxia’s trials include Canada’s first multi-dose psilocybin-assisted therapy trial which commenced in November 2021 and recently reported positive preliminary results.

Dr. McIntyre will also be available to host one-on-one meetings with institutional investors registered with H.C. Wainwright and Co.

About Braxia Scientific Corp. 

Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based disorders, such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., Braxia currently operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.

ON BEHALF OF THE BOARD

“Dr. Roger S. McIntyre”
Dr. Roger S. McIntyre
Chairman & CEO

FOR FURTHER INFORMATION PLEASE CONTACT:

Braxia Scientific Corp.

Tel: 416-762-2138

Email: info@braxiascientific.com

Website: www.braxiascientific.com

The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release. 

Forward-looking Information Cautionary Statement

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are “forward-looking statements.”

Forward-looking statements include statements about the intended promise of ketamine-based treatments for depression and the potential for ketamine to treat other emerging psychiatric disorders, such as Bipolar Depression. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the failure of ketamine, psilocybin and other psychedelics to provide the expected health benefits and unanticipated side effects, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and engaging in activities that could be later determined to be illegal under domestic or international laws. Ketamine and psilocybin are currently Schedule I and Schedule III controlled substances, respectively, under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the “CDSA”) and it is a criminal offence to possess such substances under the CDSA without a prescription or a legal exemption. Health Canada has not approved psilocybin as a drug for any indication, however ketamine is a legally permissible medication for the treatment of certain psychological conditions. It is illegal to possess such substances in Canada without a prescription.

These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, including the Amended and Restated Listing Statement dated April 15, 2021, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.

Posted on

Silo Pharma Expands License Agreement and Patent Portfolio

Silo Pharma Expands License Agreement and Patent Portfolio

Silo Enters into Commercial Evaluation License Agreement for Next Generation Liposomes

Therapeutics Would Target Multiple Diseases Including Auto Immune Disorders

ENGLEWOOD CLIFFS, N.J., June 23, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of traditional and psychedelics as a therapeutic, today announced that it has expanded its Commercial Evaluation License Agreement (CELA) with the University of Maryland Baltimore (UMB) for its next generation Liposomal Peptide targeting autoimmune diseases.

Eric Weisblum, CEO of Silo Pharma commented “We are delighted to expand our partnership with UMB.  Pre-clinical testing of these peptides has shown positive results in animal studies. The three-phage peptides we identified specifically target inflamed vascular endothelium of arthritic joints in an adjuvant-induced arthritis rat model.  To test the therapeutic effect of the peptides, arthritic Lewis rats (n=4/group) were injected intravenously with one of the peptides or PBS either at the onset or just following the onset of arthritis. The rats were monitored regularly for disease severity and were assigned an “arthritic score.” The results show treatment of arthritic Lewis rats with two of the three phage-encoded peptides (NQR and RGD) suppresses adjuvant arthritis, with RGD producing the most robust effect. Therefore, phage peptides ADK homes to the synovial vasculature of the inflamed joint, while phage peptides NQR and RGD both home to this area of the inflamed joint and have a therapeutic effect in a rat model of arthritis. The global market for auto-immune disease therapeutics is projected to be over $150 billion by 2025. We believe the issued patent portfolio that comes with these assets allows Silo to further advance its value to investors and future partners.”

About Silo Pharma 
Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information, visit www.silopharma.com

Safe Harbor and Forward-Looking Statements 
This news release contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

Investor Relations Contact: 
Hayden IR 
Brett Maas 
646-536-7331 
Email: brett@haydenir.com

Posted on

Tryp Therapeutics Appoints New Chief Operating Officer

Tryp Therapeutics Appoints New Chief Operating Officer

Sid Taubenfeld with Extensive Experience in the Financial Markets and as a Biotech Executive Joins Tryp as Company Prepares to Expand Patient Access to Psilocybin-Based Treatments

San Diego, California — (June 23, 2022) – Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that Sid Taubenfeld, a seasoned executive with healthcare and biotech expertise, has joined the Company’s senior leadership team as Chief Operating Officer.

Taubenfeld is a forward-thinking leader with over 20 years of significant experience in senior leadership roles and a deep understanding of scientific, financial, and commercial strategy. Most recently, he served as the CEO of Tikun Olam Pharma (TOP), a leading medical cannabis company based in Israel.

“Sid brings to his new role a wealth of expertise in building and growing emerging biotech companies and a strong reputation for developing people and inspiring teams,” said Jim Gilligan, Interim CEO and Chief Scientific Officer, Tryp Therapeutics. “Furthermore, his national and international experience will be a valuable asset as we continue to drive growth through our clinical trials, filed patents, and previously announced strategic actions.”

Sid’s primary responsibilities will include developing the organization’s long-term vision and strategy alongside the CEO and Board; ensuring that the company operates effectively and efficiently in all areas; and helping ensure a high-performing portfolio and psychedelic medicine advancements at Tryp.

Previously, Taubenfeld gained extensive pharmaceutical experience in a variety of executive management roles in the United States and Israel. He graduated from Brooklyn College of Pharmacy with a B.S. in Pharmacy and completed his graduate studies at New York Medical College in the area of Pharmacology.

About Tryp Therapeutics

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing psilocybin-related molecules, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-For-Neuropsychiatric Disorders (PFN™) program is focused on the development of synthetic psilocybin-related molecules as a new class of drug for the treatment of binge eating, chronic pain, and other indications. The Company has begun enrolling patients in its Phase II trial for the treatment of binge eating disorder at the University of Florida and recently announced an upcoming Phase IIa clinical trial with the University of Michigan to evaluate TRP-8802 for fibromyalgia. TRP-8803 is a proprietary psilocybin-based product that uses a novel formulation and route of administration to potentially improve efficacy, safety and the patient experience. For more information, please visit www.tryptherapeutics.com.

Investor Relations:
Jim Gilligan, Interim CEO
Tryp Therapeutics
jgilligan@tryptherapeutics.com

Media Relations:
Francesca DeMauro
KCSA Strategic Communications
TRYP@KCSA.com

Forward-Looking Information

Certain information in this news release constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans,” “targets,” “expects” or “does not expect,” “is expected,” “an opportunity exists,” “is positioned,” “estimates,” “intends,” “assumes,” “anticipates” or “does not anticipate” or “believes,” or variations of such words and phrases or state that certain actions, events or results “may,” “could,” “would,” “might,” “will” or “will be taken,” “occur” or “be achieved.” In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the “Risk Factors” section of Tryp’s final prospectus available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

Ketamine for corporate wellness

Numinus Pilots Mental Health Program for Corporate Clients in Utah

With companies investing more and more money in their employees’ mental health, psychedelic therapy could soon be included in your benefits package.

In 2019, the CBD company HempLucid partnered with Numinus Wellness (NUMI) to offer ketamine-assisted therapy to its staff members. The results were so positive that Numinus is planning to expand the corporate ketamine services to all of its 13 clinics in North America.

“It’s been revolutionary to how we operate as a business,” says HempLucid’s Founder and CEO Chase Hudson. “Offering ketamine treatments to our employees has shown incredible benefits for healing, positivity, and productivity in the work environment.

If anyone manages to negotiate ketamine therapy into their benefits package, please let us know

PDF of article

Posted on

Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond

Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond

MIAMI BEACH, Fla., June 23, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that its Chief Executive Officer, Dr. Tiago Reis Marques, will participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond, as follows:

Date:Monday, June 27, 2022
Time:10:30 a.m. ET
Location:The Lotte New York Palace Hotel

Investors participating in the conference who would like to schedule a one-on-one meeting with Pasithea’s CEO may do so by contacting their H.C. Wainwright representative or registering HERE.

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders. Pasithea is also focused on addressing the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings.

Pasithea Therapeutics Corp. Company Contact
Dr. Tiago Reis Marques
Chief Executive Officer
E: tiago@pasithea.com

Pasithea Therapeutics Corp. Investor Relations
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

Primary Logo

Source: Pasithea

Released June 23, 2022

Posted on

BetterLife To Participate at the H.C. Wainwright 1st Annual
Mental Health Conference

BetterLife To Participate at the H.C. Wainwright 1st Annual
Mental Health Conference

June 23, 2022 08:00 ET | Source: BetterLife Pharma Inc.

  • VANCOUVER, British Columbia, June 23, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that Dr. Ahmad Doroudian, Chief Executive Officer, will participate in a fireside chat at the upcoming H.C. Wainwright 1st Annual Mental Health Conference being held on June 27th, 2022 in New York City, NY.

The theme of the conference is “Neuropsychiatry, Psychedelics, and Beyond.” The fireside chat will focus on the background of BetterLife and what differentiates it in the mental healthcare space.

About BetterLife Pharma

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.

BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent for composition and method of use covers treatment of depression, cluster headaches, post-traumatic stress disorder and other neuro-psychiatric and neurological disorders.

BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife’s pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency.

BetterLife also owns a drug candidate for the treatment of viral infections such as COVID-19 and is in the process of seeking strategic alternatives for further development.

For further information, please visit BetterLife Pharma.

Contact Information

David Melles, Investor Relations Manager
Email: David.Melles@blifepharma.com
Phone: 1-778-887-1928

Cautionary Note Regarding Forward-Looking Statements

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Posted on

Delic Corp to Present Vision for Long-Term Growth and Industry-Leading Clinic Developments at First Annual H.C. Wainwright Mental Health Conference

Delic Corp to Present Vision for Long-Term Growth and Industry-Leading Clinic Developments at First Annual H.C. Wainwright Mental Health Conference

Matt Stang, CEO and Co-Founder of Delic Corp, will discuss the company’s strategic outlook for the remainder of the year and the latest developments at the nation’s largest ketamine provider, Ketamine Wellness Centers (KWC)

VANCOUVER, BRITISH COLUMBIA, June 23, 2022 – Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, confirmed details regarding Delic Corp CEO Matt Stang’s virtual attendance at the first annual H.C. Wainwright Mental Health Conference on June 27, 2022.

H.C. Wainwright Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond

June 27, 2022

Held at the Lotte New York Palace Hotel, the inaugural event will feature a full day of company presentations, networking opportunities and one-on-one investor meetings with a focus on neuropsychiatry, psychedelic and more. During this year’s conference, Stang will deliver a presentation that highlights the company’s strategic outlook for the remainder of the year and how the company is well-positioned to address the current mental health crisis. Stang will also discuss Ketamine Wellness Centers’ long-term growth strategy as the nation’s largest ketamine provider and the company’s latest patient programs such as the first-of-its-kind Veterans Administration (VA) partnership with the KWC Arizona clinics and the addition of SPRAVATO® and NAD+. His presentation will be available on June 27 starting at 7 a.m. ET. For more information regarding the first-ever H.C. Wainwright Mental Health Conference, please visit https://hcwevents.com/psychedelics/.

About Delic Corp

Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The Company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, Ketamine Wellness Centers; the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Delic Labs; the premier psychedelic wellness event, Meet Delic; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and effective treatment options to the masses.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of Delic’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to: information regarding the timing or terms upon which the Transaction will be completed; potential benefits of the Transaction; anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics); the ability of Delic to successfully achieve business ‎objectives, ‎and expectations ‎for other economic, ‎business, and/or competitive factors.‎

By identifying such information and statements in this manner, Delic is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of Delic to be ‎materially different from those ‎expressed or implied by such information and statements. Such risks and other factors may include, but are not limited to: risks and uncertainties relating to the Transaction not closing as planned or at all or on terms and conditions set forth in the Merger Agreement; incorrect assessment of the value and potential benefits of the Transaction; direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.

In addition, in connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, Delic has made certain ‎assumptions. These assumptions include, but are not limited to: assumptions as to the time required to negotiate a definite agreement and complete matters related to the Transaction; the ability to consummate the Transaction; ‎the ability of the parties to ‎obtain, in a timely manner, the requisite regulatory, corporate and other third party approvals and the satisfaction of ‎other conditions to the ‎consummation of the Transaction on the proposed terms; the potential impact of the announcement or consummation of the Transaction on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; compliance ‎with extensive government regulation; and the diversion ‎of management time on the Transaction.‎

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although Delic believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and Delic does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward-looking information and ‎statements ‎attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎

Investor Relations Contact
Rich Rodriguez
rich@deliccorp.com

Media Relations Contact
Clare Redlick
MATTIO Communications
clare@mattio.com 

Posted on

Field Trip Health Ltd. to Present at the H.C. Wainwright 1st Annual Mental Healthcare Conference on June 27, 2022

Field Trip Health Ltd. to Present at the H.C. Wainwright 1st Annual Mental Healthcare Conference on June 27, 2022

TORONTO, June 23, 2022 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) (“Field Trip”), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip’s Co-founder and Executive Chairman, Ronan Levy, and Chief Scientific Officer, Dr. Nathan Bryson, will participate in a live fireside chat at the H.C. Wainwright 1st Annual Mental Healthcare Conference taking place June 27, 2022.

Date: June 27, 2022
Time: 4:30 p.m. E.T.
Location: New York City

The fireside chat will be webcast live at 4:30 p.m. Eastern Time on Monday, June 27, through the following link: https://journey.ct.events/view/9a92c93f-2f82-4814-8d6a-22033c171e41. The webcast recording will also be accessible on Field Trip’s investor relations website and via the above link for 90 days.

Institutional investors interested in scheduling a meeting with Field Trip’s management team, please contact KCSA Strategic Communications at fieldtripIR@kcsa.com.

About Field Trip Health Ltd.

Field Trip is a global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics and our Field Trip Health division building centres for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale, we help people in need with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://www.meetfieldtrip.com, https://www.fieldtriphealth.com and https://www.fieldtriphealth.nl.

Follow us on Twitter and Instagram: @fieldtriphealth.

To receive company updates about Field Trip and to be added to the email distribution list please sign up here.

Cautionary Note Regarding Forward-Looking Information  

This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding Field Trip and its business. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including those set forth in the Company’s Annual Information Form and other market conditions, economic factors, management’s ability to manage and to operate the business and the equity markets generally. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Additional information relating to Field Trip, including its Annual Information Form, can be located on the SEDAR website at www.sedar.com and on the EDGAR section of the SEC’s website at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.

Neither the Toronto Stock Exchange, nor its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

CONTACTS:

Media contacts:
Rachel Moskowitz
Autumn Communications
202-276-7881
press@fieldtriphealth.com

Investor contacts:
Kathleen Heaney / Sophia Bashford
KCSA Strategic Communications
fieldtripIR@kcsa.com

SOURCE Field Trip Health Ltd.